Mass Spec Officials Talk M&A Progress, Strategies at UBS Conference

Life Tech and Danaher provided some more rationale on their mass-spec deal, while Waters said a potential acquirer would have to pay "top dollar" for the company. Meanwhile, Agilent snags a big pharma deal for its 1290 UHPLC, and Thermo Fisher sees brighter skies ahead.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.